Metagenomi Therapeutics (MGX) Tax Provisions (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Tax Provisions of $10000.0 for Q1 2026, down 89.8% year-over-year from $98000.0 in Q1 2025, and up 100.05% quarter-over-quarter from -$18.4 million in Q4 2025.
Metagenomi Therapeutics (MGX) Tax Provisions (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Tax Provisions for 4 consecutive years, with $10000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Tax Provisions fell 89.8% year-over-year to $10000.0; the TTM figure through Mar 2026 stood at -$18.6 million (down 242.6% YoY), while the FY2025 annual figure was -$18.5 million, down 234.92% from the prior year.
- Tax Provisions climbed to $10000.0 in Q1 2026 per MGX's latest filing, from -$18.4 million in the prior quarter.
- Across five years, Tax Provisions topped out at $2.7 million in Q4 2023 and bottomed at -$18.4 million in Q4 2025.
- Historically, Tax Provisions has averaged -$1.7 million across 4 years, with a median of -$112000.0 in 2025.
- On a YoY basis, Tax Provisions climbed as much as 102.0% in 2025 and fell as far as 1420.86% in 2025.
- Metagenomi Therapeutics' Tax Provisions stood at $2.7 million in 2023, then tumbled by 144.31% to -$1.2 million in 2024, then plunged by 1420.86% to -$18.4 million in 2025, then jumped by 100.05% to $10000.0 in 2026.
- Business Quant data shows MGX's Tax Provisions at $10000.0 in Q1 2026, -$18.4 million in Q4 2025, and -$234000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10,000.00 |
| Dec 31, 2025 | -18.37 Mn |
| Sep 30, 2025 | -234,000.00 |
| Jun 30, 2025 | 44,000.00 |
| Mar 31, 2025 | 98,000.00 |
| Dec 31, 2024 | -1.21 Mn |
| Sep 30, 2024 | -2.11 Mn |
| Jun 30, 2024 | -2.20 Mn |
| Dec 31, 2023 | 2.73 Mn |
| Sep 30, 2023 | 1.21 Mn |
| Jun 30, 2023 | 1.90 Mn |
| Mar 31, 2023 | -2.20 Mn |